Amgen (AMGN) – Major News
-
Amgen (AMGN) Tops Q4 EPS by 12c, Offers Guidance
-
Amgen (AMGN) Tops Q4 EPS by 12c; offers guidance
-
Amgen (AMGN) Tops Q3 EPS by 28c; Raises Outlook
-
Horizon Therapeutics (HZNP) and Amgen (AMGN) Resolve FTC Lawsuit, Clear Path to Close Acquisition
-
Amgen (AMGN) Settles With FTC On $27.8 Billion Horizon Deal - Bloomberg
-
Amgen (AMGN) Tops Q2 EPS by 51c; raises guidance
-
FTC Will Sue To Block Amgen's (AMGN) Deal To Buy Horizon Therapeutics (HZNP) - Bloomberg
-
Amgen (AMGN) Tops Q1 EPS by 16c
-
Amgen (AMGN) Reports In-Line Q4 EPS, Offers FY23 Guidance
-
Amgen (AMGN) acquires Horizon (HZNP) for $26 billion as Sanofi (SNY) drops bid
-
Amgen (AMGN) in advanced talks to acquire Horizon Therapeutics (HZNP) - WSJ
-
Amgen (AMGN) Tops Q3 EPS by 25c, Offers Guidance
-
Amgen (AMGN) Tops Q2 EPS by 26c, Offers Guidance
-
Amgen (AMGN) Tops Q1 EPS by 15c, Offers Guidance
-
Amgen (AMGN) Tops Q4 EPS by 24c
-
Amgen (AMGN) Tops Q3 EPS by 41c, FY Guidance Tops Consensus
-
Amgen (AMGN) Tops Q2 EPS by 32c, Reaffirms FY Guidance
-
Amgen (AMGN) Misses Q1 EPS by 35c, Revenues Miss; Reaffirms FY21 EPS/Revenues Guidance
-
Amgen (AMGN) Tops Q4 EPS by 42c
-
Amgen (AMGN) Tops Q3 EPS by 57c, Reves Beat; Raises Outlook
-
Amgen (AMGN) Tops Q2 EPS by 41c, Issues In-Line Guidance
-
Amgen (AMGN) Tops Q1 EPS by 41c
-
Amgen (AMGN) Tops Q4 EPS by 18c
-
Amgen (AMGN) will acquire 20.5% stake in BeiGene (BGNE) for approximately $2.7 billion in cash
-
Amgen (AMGN) Tops Q3 EPS by 13c, Revenues Beat; Raises FY19 EPS/Revenue Guidance
-
Amgen (AMGN) to Acquire Otezla from Celgene (CELG) for $13.4B
-
Amgen (AMGN) Tops Q2 EPS by 38c, Offers FY Guidance
-
Amgen (AMGN) Tops Q1 EPS by 8c, Updates FY Guidance
-
Amgen (AMGN) Tops Q4 EPS by 14c; Guides FY19 Below the Street
-
Amgen (AMGN) Tops Q3 EPS by 24c, FY Guidance Tops Views
-
Amgen (AMGN) Tops Q2 EPS by 29c
-
Amgen (AMGN) Tops Q1 EPS by 23c; Boosts Outlook
-
Amgen (AMGN) Misses Q4 EPS by 14c
-
Amgen (AMGN) Tops Q3 EPS by 23c
-
Amgen (AMGN) Tops Q2 EPS by 16c, Lifts FY Guidance
-
Amgen (AMGN) Announces 2nd Phase 3 Study Shows KYPROLIS (Carfilzomib) Regimen Significantly Improves Overall Survival In Patients With Relapsed Multiple Myeloma
-
Amgen (AMGN) Tops Q1 EPS by 15c, Offers FY Guidance
-
Regeneron (REGN) and Sanofi (SNY) Confirm Stay of Permanent Injunction for Praluent (AMGN)
-
Sanofi (SNY), Regeneron (REGN) Win Order Letting Praluent Sales Continue - Bloomberg
-
Amgen (AMGN) Tops Q4 EPS by 10c, Offers FY Guidance
-
Amgen's (AMGN) Repatha Trail Met Primary Endpoint in Reducing Risk of Cardiovascular Events
-
Amgen (AMGN) Wins Ban on Sanofi's (SNY) Sales of Praluent Cholesterol Drug - Bloomberg
-
Amgen (AMGN) Tops Q3 EPS by 23c
-
Amgen (AMGN) Tops Q2 EPS by 10c; Boosts FY16 Outlook
-
Amgen (AMGN) Tops Q1 EPS by 30c, Raises FY Guidance
-
Amgen (AMGN) Tops Q4 EPS by 32c, Raises FY16 Guidnce
-
Unilife Corp. (UNIS) Enters Exclusivity Agreement with Amgen (AMGN)
-
Amgen (AMGN) Tops Q3 EPS by 35c; Raises Outlook
-
Amgen (AMGN) Tops Q2 EPS by 14c, Raises FY Guidance
-
Amgen (AMGN) Tops Q1 EPS by 38c; Boosts FY15 Outlook
Back to AMGN Stock Lookup